Five healthy volunteers and 31 patients with various degrees of renal impairment received a 10-mg/kg intravenous dose of amdinocillin by infusion over 15 min to establish the disposition profile of the drug in plasma and urine. Both clearance from plasma and elimination rate constant showed a linear relationship with creatinine clearance. It was noted that in subjects with creatinine clearances of greater than 50 ml/min, the elimination half-life remained relatively constant; however, as the creatinine clearance decreased from 50 to 5 ml/min, there was a progressive rise in the elimination half-life. Despite the removal of the drug by hemodialysis (32 to 72% of the dose), concentrations of amdinocillin in plasma remained in the therapeutic range. In patients undergoing peritoneal dialysis, less than 4.0% of the infused dose was removed by dialysis during the hourly exchanges over a 14-to 18-h period. Although the clearance from plasma and the half-life of amdinocllin were altered up to fourfold in patients with creatinine clearances of less than 15 ml/min, the amdinocillin dosage per se may not need to be reduced for these patients if the frequency of dosing is reduced from six to three or four times daily. This is based on drug accumulation estimates of 56% from a regimen of 10 mg/kg every 8 h in these patients as compared with less than 10% from a regimen of 10 mg/kg every 4 h in subjects with normal renal function. In addition, supplemental doses may not be necessary during or at the end of hemodialysis for patients undergoing hemodialysis.
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Amdinocillin (also known as mecillinam) (recently approved by the Food and Drug Administration for clinical use and soon to be available under the trade name of Coactin) is an amdino penicillinate (6) which is active against a broad range of gram-negative bacteria and acts synergistically with other ,B-lactam antibiotics (2, 9, 12, 13) . The pharmacokinetics of amdinocillin in healthy human volunteers have been defined by several investigators (3, 4, 7, 8, 10) . According to these studies, amdinocillin has a relatively short elimination half-life (t1/20; 47 to 59 min), a small volume of distribution (V; 0.22 to 0.53 liter/kg), and a low clearance from plasma (CLp; 3.0 to 5.3 ml/min per kg). In addition, the fraction of a dose of amdinocillin excreted unchanged in urine (fe) is 50 to 70%, whereas biliary excretion and metabolism represent two minor pathways of elimination for amdinocillin in humans. Preliminary studies, which were limited to patients with severe-to-end-stage renal insufficiency, have shown that t1/2P of amdinocillin is prolonged in such patients (1, 11) . 11 ,um; surface area, 1.0 mi2) was used. The flow rates were 250 ml/min for blood and 500 6 .25, and 8.25 h. In patients with CLCR of <15 ml/min, the sampling schedule was modified to include a sample drawn at 10.25 h. The blood was centrifuged in a refrigerated centrifuge, and the plasma was transferred into containers suitable for immediate freezing at -75°C. The plasma was frozen within 0.5 h of specimen collection and remained frozen at this temperature until analysis. Urine was collected, when possible, at intervals between -2 to 0 (predose), 0 to 2, 2 to 4, 4 to 6, 6 to 8, and 8 to 24 h. The total volume voided for each period was recorded, and a 20-ml portion was removed, labeled, and immediately frozen at -75°C within 0.5 h of specimen collection until analysis. For patients undergoing peritoneal dialysis, the dialysate samples were collected at the end of a dwell time after the total volume of peritoneal dialysate was recorded. For patients undergoing hemodialysis, dialysate samples were taken at 1.25, 2.25, 3.25, and 4.25 h. Portions of 20 ml for each collection were labeled and stored within 0.5 h of specimen collection at -75°C until analysis.
Assay procedure. Plasma, urine, and dialysate specimens were analyzed for amdinocillin by a microbiological assay on a large plate with Escherichia coli Leo HA2 as a test organism. The microbiological assay has been shown to correlate well with the high-pressure liquid chromatographic assay by Lin et al. (5) . The plasma and urine assay were linear from 0.5 to 8 jig/ml, with a limit of detection of 0.1 ,ug/ml. The interassay precision for plasma was 11.7% at the 10-,ug/ml concentration and 14.1% at the 100-,ug/ml concentration after appropriate dilution with water. The interassay precision for urine averaged 6.7% over the 10-to 2,000-,ug/ml range.
Pharmacokinetic analysis. The following pharmacokinetic parameters were estimated from the plasma and urine concentration-time profiles: (i) area under the plasma concentration-time curve from time zero to infinity, by conventional trapezoidal summation and extrapolation methods; (ii) the impairment, and the extent of this elevation was directly related to the increasing degree of renal impairment (Fig. 1) .
The t1/2P of amdinocillin was progressively increased, and
CLp was progressively decreased as the severity of renal impairment increased (Table 2 ). Both CLp and d demonstrated a linear relationship with CLCR ( Fig. 2 and 3) . It was noted that in subjects with CLCR of greater than 50 ml/min, the t1/2, remained relatively constant; however, as CLCR decreased from 50 to 5 ml/min, there was a progressive rise in t1/2P (Fig. 4) . The mean V in patients with mild, moderate, or severe renal impairment was generally similar to that in healthy volunteers ( Table 2) . As expected,fe decreased from 44% in healthy volunteers to 42, 23, and 9.6% in patients with mild, moderate, or severe renal impairment, respectively (Table 2) . Compared with those in patients with severe renal impair-
ment or patients undergoing peritoneal dialysis, average concentrations of amdinocillin in plasma were lower in patients who underwent hemodialysis (Fig. 5) , because 32 to 72% of the administered dose was dialyzed and recovered in the dialysate ( Table 2 ). The loss of amdinocillin in the dialysates of patients who underwent peritoneal dialysis was negligible (less than 4.0%; Table 2 urine are reported in Table 3 . Concentrations of amdinocillin in the urine of patients with severe renal impairment were generally lower than those found for other groups; however, these concentrations greatly exceeded the MICs for the invading pathogens responsible'for the urinary tract infections (2, 9, 12, 13) . with severe-to-end-stage renal disease were consistent with the preliminary observations of Svarva and Wessel-aas (11) and Bailey et al. (1) . The study of Svarva and Wessel-aas (11) showed that t4/20 for amdinocillin ranged from 4.4 to 7.6 h, with a mean of 5.6 h, in nine patients (CLCR, <16 ml/min) who were treated with amdinocillin for urinary tract infection. Bailey et al. (1) VOL. 28, 1985 tion in plasma for patients with severe renal impairment would be 18.8 ,ug/ml and 56%, respectively, from a regimen of 10 mg/kg every 8 h.
In summary, with increasing renal impairment the CLp of amdinocillin is decreased and its tl2.v is increased. Although the CLp and tl2p of amdinocillin were altered up to fourfold in patients with a CLCR of 0 to 15 ml/min, the amdinocillin dosage may not have to be reduced for these patients if the frequency of dosing is reduced from six to three or four times daily.
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